

• Appl. No. 10/089,058
• Response dated April 11, 2005
• Reply to Office action of February 11, 2005

REMARKS/ARGUMENTS

Applicant provisionally elects Group II, the claims readable thereon as being claims 13-21, 37-38 and 42 and 45, which are drawn to proteins. This is without prejudice to Applicant filing a divisional application to the Group I, III and IV inventions.


Applicant further elects ricin A and ricin B and the following ten sequences. In claims 13 and 42: PAP301 (Seq ID No. 7), PAP302 (Seq ID No. 14), PAP303 (Seq ID No. 21), PAP304 (Seq ID No. 28), PAP305 (Seq ID No. 35), PAP308 (Seq ID No. 42), PAP316 (Seq ID No. 77), PAP323 (Seq ID No. 112), PAP324 (Seq ID No. 119), and PAP325 (Seq ID No. 126). The election of ricin A and ricin B is made with traverse. We respectfully submit that the ricin-like toxins share a common inventive concept which the Examiner can readily search without undue burden. We point out that Applicant has had other cases issue in the United States without requiring restriction to specific toxins. In this regard we refer to U.S. Patent Nos. 6,333,303 and 6,531,125.

The Commissioner is hereby authorized to charge any fee (including any claim fee) which may be required to our Deposit Account No. 02-2095.

In view of the foregoing comments and amendments, we respectfully submit that the application is in order for allowance and early indication of that effect is respectfully requested. Should the Examiner deem it beneficial to discuss the application in greater detail, he is kindly requested to contact the undersigned by telephone at (416) 957-1682 at his convenience.

Respectfully submitted,

BERESKIN & PARR

By 

Tina Loucaides
Reg. No. 56,622
For
Micheline Gravelle
Reg. No. 40,261

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario
Canada M5H 3Y2
Tel: 416-957-1682
Fax: 416-361-1398